Compare Plug Power Inc (PLUG) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Plug Power Inc vs Spyre Therapeutics Inc. Common Stock — how do they compare? Plug Power Inc trades at $1.44 (market cap $2.18B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Spyre Therapeutics Inc. Common Stock is far larger — about 3.4× Plug Power Inc's market cap, and Spyre Therapeutics Inc. Common Stock is trading nearer its 52-week high, Plug Power Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Plug Power Inc for 42 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| PLUG | SYRE | |
|---|---|---|
Market Cap | $2.18B | $7.52B |
Volume | 58,569,311 | 1,441,031 |
Sector | Industrials | Health |
52-Week High | $4.14 | $108.92 |
52-Week Low | $1.45 | $22.18 |
Typical Hold Time | 42 Days | 0 Days |
Enterprise Value | $3.05B | $6.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Plug Power (PLUG) trades at $1.45, down 10.49% today, reflecting ongoing operational challenges. The stock shows bearish technical signals with negative moving averages, while fundamentals reveal persistent losses with a -220.59% net income margin and negative cash flow. Recent news highlights strategic partnerships including a 280 MW electrolyzer agreement with Arcadia eFuels, but the company continues to miss earnings expectations consistently.
Despite analyst consensus favoring Buy ratings (44.73%), PLUG faces significant execution risks with negative profitability and high cash burn. The $3.33 price target suggests potential upside if green hydrogen adoption accelerates, but investors must weigh substantial operational losses against long-term growth prospects in the clean energy sector.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Plug Power Inc
Plug Power is building an end-to-end green hydrogen ecosystem—from production, storage and delivery to energy generation. The company plans to build and operate green hydrogen highways across North America and Europe. Plug will deliver its green hydrogen solutions directly to its customers and through joint venture partners into multiple end markets—including material handling, e-mobility, power generation, and industrial applications.
Read more on PLUG →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
